Resources

At FTI Consulting, working closely with the BIA’s Finance and Treasury Committee and HMRC, we have devoted a great deal of time interpreting the new legislation for qualifying overseas expenditure and guidance.

In this blog, Matej Metkovic, CEO and Founder of Wasteless Bio, explores the valuable unused equipment sitting in labs that quietly erodes in worth.

Proceeds will enable generation of full clinical data from ongoing Phase 1 study of TROCEPT-01 (ATTR-01), its lead programme in advanced solid tumours, and progression of TROCEPT-02 (ATTR-02) into the clinic.

Relation today announced a further $26 million investment from existing investors NVentures (NVIDIA’s venture capital arm) and leading deeptech investors DCVC and Magnetic Ventures.

Relation Therapeutics has announced a multi-program, strategic collaboration with Novartis to discover and advance novel targets for atopic diseases.

In this analysis by Dr Martin Turner, Director of Policy and External Affairs, BIA, discover how the 2025 Budget could supercharge UK life sciences scale-ups with major investment incentives - while also highlighting potential risks from rising business rates.

Read our statement welcoming the Chancellor’s extended venture investment tax incentives and support for employee share options, as well as the prioritisation of tax and spending decisions in areas where the UK can lead and win.

In this blog, Lewis Miles, Policy and Public Affairs Manager at the BIA, reflects on an intense period of engagement with Ministers and Parliament ahead of the Autumn Budget.

London Life Sciences Week was a huge success last week, with significant increase in investors and life sciences execs coming together to connect and network.  Combined with the news of two new significant fund raises from Sofinnova and Medicxi and progress towards completion of the British Growth Partnership Fund, it did feel that the sector found a lot to be hopeful about. 

T-Therapeutics, a biotechnology company developing next-generation T cell receptor (TCR) therapeutics for cancer and autoimmune disease, today announces the successful expansion of its Series A financing, raising afurther $32 million. Following the initial $59 million raised, this brings the Series A total to date to $91 million.

The British Business Bank has announced a €30 million commitment to Sofinnova Partners (Sofinnova) new €650 million ($750 million) fund, Sofinnova Capital XI. 

BIA’s influence and connect were out in force last week – grasping a timely opportunity to get our key Autumn Budget asks across impactfully to the Chancellor with the clear backing of over 200 member CEOs, and putting on a dynamic, pro-innovation Future of UK Regulation conference, featuring MHRA and NICE CEOs amongst other key stakeholders.

As discussion around the Autumn Budget heats up, BIA is leading a unified call to the Chancellor to back the science, the entrepreneurs and the life sciences industry that can fuel transformational growth for the UK economy. Our sector letter highlights key growth levers and indeed the barriers that hold the sector back in already challenging global conditions. 

AAVantgarde's Stargardt disease and Usher syndrome Ib programmes address the root genetic causes of devastating conditions and offer hope of improvement to patients and families living with progressive vision loss.

Thermo Fisher Scientific Inc. announced a definitive agreement to acquire Clario Holdings, Inc., a leading provider of endpoint data solutions for clinical trials, from a shareholder group led by Astorg and Nordic Capital, Novo Holding and Cinven, for $8.875 billion.

The UK biotech financing numbers for Q3 are out, showing validation of UK assets but a sector under strain from prolonged global headwinds. Time to double down on investment in innovation as a driver for growth and deploy Industrial Strategy plans with urgency.